PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast by Boswell-Smith, Victoria & Spina, Domenico
International Journal of COPD 2007:2(2) 121–129
© 2007 Dove Medical Press Limited. All rights reserved
121
REVIEW
PDE4 inhibitors as potential therapeutic agents 
in the treatment of COPD-focus on roﬂ  umilast
Victoria Boswell-Smith
Domenico Spina
The Sackler Institute of Pulmonary 
Pharmacology, King’s College London 
School of Biomedical and Health 
Sciences, King’s College London, 
Guys Campus, UK
Correspondence: Domenico Spina
The Sackler Institute of Pulmonary 
Pharmacology, King’s College London 
School of Biomedical and Health Sciences, 
King’s College London, 5th Floor, Hodgkin 
Building, Guys Campus, UK, SE1 1UL
Tel +44 20 7848 6114
Fax +44 20 7848 6097
Email domenico.spina@kcl.ac.uk
Abstract: Chronic obstructive pulmonary disease is characterized by a rapid decline in lung 
function due to small airway ﬁ  brosis, mucus hypersecretion and emphysema. The major caus-
ative factor for COPD is cigarette smoking that drives an inﬂ  ammatory process that gives rise 
to leukocyte recruitment, imbalance in protease levels and consequently matrix remodeling 
resulting in small airway ﬁ  brosis and loss of alveolar tissue. Current drug treatment improves 
symptoms but do not alter the underlying progression of this disease. The failure of anti-
inflammatory drugs like glucocorticosteroids to have a major impact in this disease has hastened 
the need to develop novel therapeutic strategies. Phosphodiesterase (PDE)4 inhibitors are novel 
anti-inﬂ  ammatory drugs that have recently been show to document clinical efﬁ  cacy in this 
disease, although their utility is hampered by class related side-effects of nausea, emesis and 
diarrhea. Whilst it is not yet clear whether such drugs will prevent emphysema, this is a distinct 
possibility provided experimental observations from preclinical studies translate to man. This 
review will discuss the current standing of PDE4 inhibitors like roﬂ  umilast as novel treatments 
for COPD and the potential for developing nonemetic anti-inﬂ  ammatory drugs. 
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a respiratory condition associated 
with emphysema and chronic bronchitis. The major risk factor for the development 
of this disease is tobacco smoking and the most effective way to prevent the devel-
opment of the disease is not to smoke (Lenfant and Khaltaev 2005; Bergeron and 
Boulet 2006). COPD is currently diagnosed in 4% of men and 2% of women and if 
these trends continue is predicted to be the sixth leading cause of death worldwide by 
2020 as the number of people who smoke worldwide continues to rise, although other 
factors including exposure to smoke from biomass fuels particularly in developing 
countries may also contribute toward disease morbidity (Pauwels et al 2005; Lenfant 
and Khaltaev 2005). The direct economic cost of COPD in the United Kingdom 
based on 1996 ﬁ  gures has been estimated at approximately £846 million and the 
disease accounts for a large proportion of long-term NHS hospitalizations (Pauwels 
et al 2005; Lenfant and Khaltaev 2005; SRBS 2006). The drugs used in the treatment 
of COPD have not appreciably changed in the last 25 years and as a result there is 
clearly a need for novel therapeutic agents to reduce disease progression and possibly 
reverse the decline in lung function seen with this disease (Barnes and Stockley 2005). 
Phosphodiesterase (PDE)4 inhibitors are a novel class of drug in development for the 
treatment of COPD and to date the most promising compound to arise from preclinical 
and clinical development is Roﬂ  umilast (Daxas®; Figure 1) and this review will focus 
on the clinical experience with this drug for the treatment of COPD. International Journal of COPD 2007:2(2) 122
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Chronic obstructive pulmonary 
disease
Although the diagnosis and mortality rate of COPD continues 
to increase there are currently no drugs available which can 
treat the inﬂ  ammation and emphysematous change under-
lying this chronic disease. In addition, the majority of the 
drugs used to treat COPD were not speciﬁ  cally designed 
solely to treat this condition but were developed to treat 
asthmatics and therefore may not be ideal therapeutics. Drugs 
frequently used in the management of COPD as recom-
mended by the World Health Authority (WHO) and GOLD 
include β2-agonists such as salbutamol and salmeterol, 
anti-cholinergic agents including ipatropium bromide and 
tiotropium bromide, methylxanthines and inhaled glucocorti-
costeroids (Pauwels et al 2005; Lenfant and Khaltaev 2005). 
Although these drugs have proved to reduce exacerbations 
and reduce symptoms there is little evidence to suggest they 
can reduce the progression of this disease. Other pharmaco-
logic interventions frequently used in the management of 
COPD include antibiotics, mucolytic agents, antioxidants, 
immunoregulators, anti-tussives, respiratory stimulants and 
vasodilators. Therefore, there is a real requirement for drugs 
which can prevent the further damage to and loss of alveoli 
by targeting the inﬂ  ammatory processes which are activated 
in the COPD lung. 
The major genetic cause of COPD is α1 anti-trypsin 
deficiency, which can lead to early onset emphysema 
particularly in individuals who also smoke. However, this 
deﬁ  ciency accounted for a relatively small proportion of 
diagnosed cases (Stoller and Aboussouan 2005) and the 
major environmental risk factor underlying the development 
of COPD is cigarette smoking. It has been estimated that 
between 15%–20% of smokers will develop this disease 
(Pauwels et al 2005). Inhaled cigarette smoke activates 
resident cells in the lungs including epithelial cells and 
alveolar macrophages which have the capacity to release 
cytokines, chemokines and lipid mediators including 
TNFα, IL-8, TGF-β, and LTB4 resulting in the recruitment 
and activation of inﬂ  ammatory cells which subsequently 
release a cocktail of proteases into the matrix compartment 
that can provoke a complex remodelling process leading to 
alveolar wall destruction, mucus hypersecretion and peri-
bronchiolar ﬁ  brosis (Barnes et al 2003; Hogg 2004; Barnes 
and Stockley 2005; Bergeron and Boulet 2006). Over time, 
perpetuation of the inﬂ  ammatory response by continual 
exposure to cigarette smoke in combination with impaired 
repair processes can manifest in the pathology and clinical 
symptoms of COPD. In addition, it is evident that exposure 
to tobacco smoke can induce an oxidant/antioxidant imbal-
ance in favor of oxidative stress. There is also evidence that 
although smoking cessation can be beneﬁ  cial, inﬂ  ammation 
can perpetuate in patients with COPD long after they stop 
smoking (Retamales et al 2001; Shapiro 2001). Therefore, 
targeting the inflammation and remodeling processes 
associated with COPD may slow down disease progres-
sion and potentially reverse the decline in lung function 
in these patients. 
Whilst smoking cessation and abstinence provide the best 
approach for the treatment of this disease the pharmaceutical 
industry are developing molecules which target a number 
of mediators including LTB4, IL-8, TNF-α, and proteases 
which are known to contribute to the lung damage within 
this disease (Barnes and Stockley 2005), however, the clini-
cal utility of targeting a single mediator is unlikely to be of 
any therapeutic beneﬁ  t due to the overlapping roles played 
by the various mediators released within the inﬂ  ammatory 
milieu. Anti-inﬂ  ammatory drugs like glucocorticosteroids 
which are know to inhibit the activity of inﬂ  ammatory 
cells and production of cytokines and chemokines might 
be expected to be of beneﬁ  t in this disease. However, the 
clinical experience with this particular drug class in COPD 
has been disappointing and it has been suggested that the 
lack of efﬁ  cacy of these drugs in this disease is attributable 
to a molecular defect in histone deacetylase activity (Ito 
et al 2005). As a consequence, other anti-inﬂ  ammatory 
drugs are currently being developed for the treatment of 
COPD which include the PDE4 inhibitors. The advantage 
of this approach is that drugs of this nature have the ability 
of suppressing the release of a wide range of inﬂ  ammatory 
mediators, cytokines, chemokines, and proteases from cells 
implicated in this disease and therefore, offer signiﬁ  cant 
advantages over drugs that target single mediators or single 
biochemical pathways.
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Figure 1 Structure of roﬂ  umilast.International Journal of COPD 2007:2(2) 123
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PDE4: relevance to COPD
Phosphodiesterases are ubiquitous enzymes which hydrolyse 
the cyclic nucleotides; cyclic adenosine-3,5- monophosphate 
(cAMP) and cyclic guanosine -3,5- monophosphate (cGMP), 
to their inactive 5′nucleotide monophosphate, 5′ AMP and 5′ 
GMP respectively (Essayan 2001). A great deal is now known 
about the phosphodiesterase enzymes and eleven families 
(1–11) have now been identiﬁ  ed based on substrate speciﬁ  c-
ity, enzyme kinetics and distribution and inhibitor potency 
(Essayan 2001). PDE4 is a cAMP speciﬁ  c phosphodiester-
ase which is located predominantly to inﬂ  ammatory cells, 
including cells important to the pathogenesis of COPD such 
as neutrophils, macrophages, lymphocytes, ﬁ  broblasts and 
airway smooth muscle. PDE4 is encoded by 4 genes PDE4A, 
PDE4B, PDE4C, and PDE4D each of which has unique cel-
lular distribution and function (Houslay 2001). Elevation of 
cAMP in structural and inﬂ  ammatory cells within the lung can 
provide an anti-inﬂ  ammatory action in the context of COPD 
and this can be achieved by inhibiting PDE4 in target cells 
(Sanz et al 2005). For example, PDE4 inhibitors like roﬂ  u-
milast (Figure 1) suppressed a variety of functions ascribed 
to neutrophils including protease (neutrophil elastase, matrix 
metalloprotease 9) and myeloperoxidase release (Jones et al 
2005); oxygen radical production (Hatzelmann and Schudt 
2001); and adhesion to endothelial cells (Jones et al 2005) by 
inhibiting the expression of β2-integrins in these cells (Derian 
et al 1995). Similarly, PDE4 inhibitors including roﬂ  umilast 
suppress the proliferation and cytokine release from CD4+, 
CD8+ lymphocytes (Hatzelmann and Schudt 2001; Landells 
et al 2001; Smith et al 2004) that may involve inhibition of 
several intracellular signalling pathways including activation 
of NF-κB a well known pro-inﬂ  ammatory transcription fac-
tor (Kwak et al 2005). Additionally, cytokine release from 
mononuclear cells, including that of the pro-inﬂ  ammatory 
cytokine TNF-α, which is elevated in sputum from patients 
with COPD (Keatings et al 1996), can be inhibited by PDE4 
inhibitors (Hatzelmann and Schudt 2001). Together these 
studies indicate that inﬂ  ammatory cell recruitment and activ-
ity can be inhibited by PDE4 inhibitors. 
The effect of PDE4 inhibitors upon the activity of resident 
cells within the lung including, ﬁ  broblasts, macrophages, and 
epithelial cells, which are relevant to COPD has also been 
investigated. Whilst macrophages do express PDE4 it appears 
that their function is poorly inhibited by PDE4 inhibitors, 
although the efﬁ  cacy of these drugs is enhanced when used 
in combination with agents that raise intracellular levels of 
cyclic AMP (eg, prostaglandin E2) or if there is concurrent 
inhibition of PDE3 and PDE7 (Hatzelmann and Schudt 2001; 
Smith et al 2004). The expression of PDE3 and PDE7 is 
increased during differentiation of monocytes to macro-
phages and thereby play a greater role in regulating intracel-
lular levels of cyclic AMP in this cell type (Hatzelmann and 
Schudt 2001; Smith et al 2004). An important implication of 
these experimental observations is that PDE4 inhibitors may 
only be partially effective in COPD in view of the proposed 
role of macrophages in this disease (Barnes and Stockley 
2005) and there is therefore a case for the potential develop-
ment of dual PDE inhibitors in the context of COPD (Smith 
et al 2004; Boswell-Smith et al 2006). 
The proposed role of macrophage derived MMP12 in 
the emphysematous changes to the lung in chronic smoking 
models in mice (Shapiro et al 2003) would suggest that PDE4 
inhibitors will be ineffective at inhibiting emphysematous 
changes to the lung. However, this is not consistent with the 
ﬁ  ndings from a number of preclinical models indicating that 
PDE4 inhibitors can prevent the development of emphysema 
in these models (Martorana et al 2005; Leclerc et al 2006) 
and whilst the exact molecular target was not identiﬁ  ed, the 
suppression of TNFα production and downstream signalling 
by this cytokine is inferred, in view of the important role 
this cytokine plays in the development of emphysema in this 
model (Churg et al 2004). Further studies are required to 
determine the precise role of PDE4 in modulating MMP12 
synthesis and release from alveolar macrophages. Other 
studies have demonstrated that PDE4 inhibitors can suppress 
ﬁ  broblast chemotaxis and contraction of native collagen gels, 
a measure of ﬁ  broblast activity (Kohyama et al 2002) and the 
release of two matrix metalloproteases, pro-MMP-1 and 2, from 
activated isolated human lung ﬁ  broblasts (Martin-Chouly 
et al 2004) which is of particular interest in view of the 
potential role of MMP’s in the development of small airway 
ﬁ  brosis and emphysema (Barnes et al 2003). Together, these 
studies demonstrate that PDE4 inhibitors have the potential 
to modulate the structural changes induced by these proteases 
in the lung by preventing their release from the appropriate 
recruited and or resident cell. 
The release of the pro-inﬂ  ammatory mediators PGE2, IL-8 
and 15-HETE from isolated epithelial cells was unaffected 
by the PDE4 inhibitors rolipram and roﬂ  umilast (Dent et al 
1998; Fuhrmann et al 1999). However, rolipram suppressed 
bacterial-induced epithelial damage of the bronchial mucosa 
and cilomilast suppressed TNF-α release from epithelial 
cells taken from COPD patients (Proﬁ  ta et al 2003). In addi-
tion roﬂ  umilast attenuated epithelial growth factor-induced 
MUC5AC mRNA and protein expression in isolated 
human airway epithelial cells providing evidence that PDE4 International Journal of COPD 2007:2(2) 124
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inhibitors may suppress mucus secretion in airways disease 
(Mata et al 2005). Collectively, these data demonstrate that 
in isolated cell populations these drugs demonstrate potent 
anti-cellular activity.
With respect to airways smooth muscle, there is little 
evidence that PDE4 inhibitors including roﬂ  umilast are potent 
relaxant agonists. Human bronchial preparations gain tone 
spontaneously and this is mediated by the contractile effects 
of endogenously liberated leukotrienes and histamine (Ellis 
and Undem 1994). However, PDE4 inhibitors only weakly 
suppressed spontaneously generated tone, or contractions of 
isolated human airways smooth muscle in response to allergen, 
LTC4, and histamine, although this functional antagonism is 
signiﬁ  cant when combined with a PDE3 inhibitor (Schmidt et 
al 2000). These data suggest that PDE4 inhibitors would not 
be expected to have signiﬁ  cant bronchodilator efﬁ  cacy when 
administered alone (Engelstatter et al 2005) and in allergic 
asthma, roﬂ  umilast demonstrated very modest activity in 
preventing acute bronchoconstriction to allergen challenge 
(Van Schalkwyk et al 2005) which is in stark contrast to the 
well known bronchoprotective activity of β2-adrenoceptor 
agonists.
There are no satisfactory animal models of COPD and so 
there is a general reliance on using models that measure the 
effect of anti-inﬂ  ammatory drugs on neutrophil recruitment to 
the airways in response to a given stimulus (eg, LPS) although 
it is clear that this particular stimulus may not be discrimina-
tory for the development of anti-inﬂ  ammatory drugs for the 
treatment of COPD (Leclerc et al 2006). The effect of drugs 
on matrix turnover and tissue damage is being used to assess 
the potential utility of novel agents against emphysematous 
changes seen with following cigarette smoke exposure (Churg 
et al 2002; Leclerc et al 2006), although very few studies 
attempt to measure changes in pulmonary mechanics (eg,   
lung compliance) as an index of any physiological change of 
lung function to the various insults directed against the lung. 
Notwithstanding these challenges, a number of preclinical 
studies have shown that PDE4 inhibitors have the capacity 
to suppress the recruitment of neutrophils (Bundschuh et al 
2001; Spond et al 2001; Leclerc et al 2006), and mucus 
hypersecretion (Sturton and Fitzgerald 2002) in rodents 
challenged with LPS; and reverse sub epithelial ﬁ  brosis and 
hypertrophy in a murine model of asthma (Kumar et al 2003). 
Furthermore, PDE4 inhibitors including roﬂ  umilast prevented 
parenchymal damage and suppressed indices of inﬂ  ammation 
in mice exposed to cigarette smoke indicating that these drugs 
could prevent further emphysematous changes to the lung in 
COPD (Martorana et al 2005; Leclerc et al 2006).
Despite these very positive preclinical findings, the 
clinical development of PDE4 inhibitors has progressed 
slowly due to the dose limiting side effects associated with 
this drug class. Cilomilast is 10-fold more selective for 
PDE4D compared with other PDE4 subtypes, and might 
explain its propensity to cause gastrointestinal adverse 
events that include nausea and diarrhoea (Rennard et al 
2006). Similarly, whilst roﬂ  umilast does not demonstrate 
any PDE4 subtype selectivity and is two orders of magnitude 
more potent than cilomilast (Hatzelmann and Schudt 2001), 
COPD patients treated with this drug also experience side-
effects like nausea and diarrhea (Rabe et al 2005). 
Interestingly, the adverse events experienced by individuals 
appeared to diminish over the course of the study and 
the mechanistic basis of this observation remains to be 
established (Rabe et al 2005). The presence of PDE4 in 
parietal cells and emetic centres (area postrema, nucleus 
tractus solitaris) provide an explanation for the incidence of 
these side effects following administration of this drug class. 
There has been some attempt to ascertain whether speciﬁ  c 
PDE4 subtypes exist in these regions and therefore offer 
the possibility of developing nonemetic subtype selective 
PDE4 inhibitors. Both PDE4B and PDE4D are found within 
the nucleus tractis solitaris in man and rodents (Takahashi 
et al 1999; Cherry and Davis 1999; Perez-Torres et al 2000) 
whilst studies in the squirrel monkey have only demonstrated 
PDE4D in the area postrema with many neurones also 
positive for substance P (Lamontagne et al 2001). Since 
PDE4B and not PDE4D appear to play an important role in 
neutrophilic inﬂ  ammation (Jin and Conti 2002), suggests that 
PDE4 inhibitors with low selectivity for PDE4D could prove 
to be novel nonemetic anti-inﬂ  ammatory drugs (Lamontagne 
et al 2001). It remains to be established however, to what 
extent PDE4B plays a role in nausea and emesis given its 
presence within the nucleus tractus solitaris (Perez-Torres 
et al 2000; Lamontagne et al 2001) and this issue will only be 
resolved by examining the effect of PDE4 subtype selective 
inhibitors in models of emesis.
Clinical ﬁ  ndings with roﬂ  umilast
Two potent PDE4 inhibitors cilomilast (Ariflo®) and 
roflumilast (Daxas®) and have progressed farthest in 
development and are in late Phase III clinical trials (Lipworth 
2005; Giembycz 2006) but only the ﬁ  ndings for roﬂ  umilast 
will be considered in this review (Table 1). Roﬂ  umilast has 
undergone wide-scale clinical investigation in patients with 
COPD. It is an orally-active compound (bioavailability 
79%) and can be administered once daily due to its favorable International Journal of COPD 2007:2(2) 125
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pharmacokinetics. Roﬂ  umilast is metabolized to its active 
metabolite roﬂ  umilast N-oxide which is only 2–3-fold less 
potent than the parent compound, and whose plasma levels 
remain elevated for up to 24 hours (David et al 2004). Ro-
ﬂ  umilast is safe and well tolerated and no signiﬁ  cant interac-
tions with other drugs routinely prescribed to COPD patients 
including salbutamol (Weimar et al 2002), budesonide 
(Hunnemeyer et al 2002a) and warfarin (Hauns et al 2003) 
have been reported. Furthermore, roﬂ  umilast has no reported 
interactions with cigarette smoke, which makes it safe for 
smokers to use (Hunnemeyer et al 2002b). 
The efﬁ  cacy of roﬂ  umilast was assessed by monitoring 
forced expiratory volume in one second (FEV1), forced vital 
capacity (FVC), morning peak expiratory ﬂ  ow (PEF) and 
exacerbation rates in a double-blind, placebo controlled trial 
of 516 mild-moderate COPD subjects (post bronchodilator 
FEV1 between 35 and 75%) given either placebo, or roﬂ  umi-
last (250 μg or 500 μg) once daily for 26 weeks. Roﬂ  umilast 
dose-dependently improved lung function and exacerbation 
rates (48% reduction in 500 μg group) (Leichtl et al 2002a). 
Importantly, roﬂ  umilast was safe and well tolerated with 
the most frequently described adverse events being nausea 
(2%), headache (2%) and diarrhoea, which were mostly 
mild – moderate in nature (Leichtl et al 2002b). 
In a larger multi-centre 24 week trial (OPUS trial), 1411 
patients were administered either roﬂ  umilast (250 μg or 500 
μg) or placebo once daily. Outcome measurements in this 
study included lung function, health related quality of life 
using the St George’s Respiratory Questionnaire (SGRQ) and 
exacerbation rate. There was a signiﬁ  cant improvement in 
post-bronchodilator FEV1 in the treatment groups compared 
with the control groups. Furthermore, quality of life scores 
also improved in the roﬂ  umilast-treated patients compared 
with patients treated with placebo; although this was not 
found to be signiﬁ  cant. Comparison of the mean exacerbation 
rates demonstrated this was 34% lower in the roﬂ  umilast 
(500 μg) group compared with the placebo treated group 
(Rabe et al 2005). Recent results released by Altana (2005) 
in a press release from another Phase III clinical trial (RATIO 
study) of 1513 patients with severe and very severe COPD 
were also encouraging. Roﬂ  umilast (500 μg) treatment sig-
niﬁ  cantly improved post-bronchodilator FEV1 in these more 
severe patients and induced signiﬁ  cant reduced moderate 
exacerbations of COPD although it did not signiﬁ  cantly af-
fect the overall exacerbation rate (Altana 2005). 
In a further placebo controlled study, 581 subjects with 
COPD were given roﬂ  umilast (500 μg) or placebo for the 
full 24 weeks of study or roﬂ  umilast for the ﬁ  rst 12 weeks 
T
a
b
l
e
 
1
 
(
C
o
n
t
i
n
u
e
d
)
S
t
u
d
y
T
r
i
a
l
 
d
e
s
i
g
n
P
r
i
m
a
r
y
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
m
e
n
t
s
F
i
n
d
i
n
g
s
R
e
f
e
r
e
n
c
e
W
i
t
h
d
r
a
w
a
l
 
S
t
u
d
y
(
5
8
1
 
s
u
b
j
e
c
t
s
)
F
E
V
1
 
3
5
%
–
7
5
%
 
p
r
e
d
i
c
t
e
d
 
R
o
ﬂ
 
u
m
i
l
a
s
t
 
(
5
0
0
 
μ
g
)
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
 
f
o
r
 
1
2
 
w
e
e
k
s
P
o
s
t
-
b
r
o
n
c
h
o
d
i
l
a
t
o
r
 
F
E
V
1
I
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
d
r
a
w
i
n
g
 
f
r
o
m
 
r
o
ﬂ
 
u
m
i
l
a
s
t
 
F
E
V
1
 
s
l
o
w
l
y
 
d
e
c
l
i
n
e
d
 
o
v
e
r
 
w
e
e
k
s
 
b
u
t
 
r
e
m
a
i
n
e
d
 
a
b
o
v
e
 
p
l
a
c
e
b
o
 
l
e
v
e
l
s
B
o
s
z
o
r
m
e
n
y
i
-
N
a
g
y
 
e
t
 
a
l
 
2
0
0
5
S
a
f
e
t
y
(
3
9
7
 
s
u
b
j
e
c
t
s
)
P
o
s
t
-
b
r
o
n
c
h
o
d
i
l
a
t
o
r
 
F
E
V
1
 
(
3
5
%
–
7
5
%
 
p
r
e
d
i
c
t
e
d
)
R
o
ﬂ
 
u
m
i
l
a
s
t
 
(
5
0
0
 
μ
g
)
,
 
5
2
 
w
e
e
k
s
A
d
v
e
r
s
e
 
e
v
e
n
t
s
 
4
9
%
 
d
u
r
i
n
g
 
d
o
u
b
l
e
 
b
l
i
n
d
 
p
e
r
i
o
d
 
(
s
a
m
e
 
f
r
e
q
u
e
n
c
y
 
a
l
l
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
)
 
4
1
%
 
d
u
r
i
n
g
 
o
p
e
n
 
l
a
b
e
l
 
s
t
u
d
y
.
 
M
o
s
t
 
m
i
l
d
 
t
o
 
m
o
d
e
r
a
t
e
 
a
n
d
 
t
r
a
n
s
i
e
n
t
 
i
n
 
n
a
t
u
r
e
>
9
0
%
 
u
n
r
e
l
a
t
e
d
 
t
o
 
s
t
u
d
y
 
d
r
u
g
1
0
 
p
a
t
i
e
n
t
s
 
(
2
.
5
%
)
 
e
x
p
e
r
i
e
n
c
e
d
 
1
3
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
w
h
i
c
h
 
w
e
r
e
 
d
e
ﬁ
 
n
i
t
e
l
y
 
r
e
l
a
t
e
d
 
t
o
 
s
t
u
d
y
 
d
r
u
g
.
 
3
 
l
e
a
d
 
t
o
 
s
t
u
d
y
 
d
i
s
c
o
n
t
i
n
u
a
t
i
o
n
B
a
t
e
m
a
n
 
e
t
 
a
l
 
2
0
0
4
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
C
O
P
D
,
 
c
h
r
o
n
i
c
 
o
b
s
t
r
u
c
t
i
v
e
 
p
u
l
m
o
n
a
r
y
 
d
i
s
e
a
s
e
;
 
F
E
V
1
,
 
f
o
r
c
e
d
 
e
x
p
i
r
a
t
o
r
y
 
v
o
l
u
m
e
 
i
n
 
o
n
e
 
s
e
c
o
n
d
;
 
I
L
,
 
i
n
t
e
r
l
e
u
k
i
n
;
 
S
D
,
 
s
t
a
n
d
a
r
d
 
d
e
v
i
a
t
i
o
n
.International Journal of COPD 2007:2(2) 127
Roﬂ  umilast in COPD
followed by placebo for the remaining 12 weeks. Roﬂ  umilast 
signiﬁ  cantly improved post-bronchodilator FEV1 compared 
with placebo (p = 0.0003) which were maintained throughout 
the 24 weeks of study. In the patients where roﬂ  umilast was 
withdrawn after 12 weeks, there was a slow decline in FEV1 
but it still remained above placebo levels by the end of the 
study (Boszormenyi-Nagy et al 2005). 
Since PDE4 inhibitors are weak bronchoprotective drugs 
it seems highly probable that these small improvements in 
FEV1 can be attributed to the anti-inﬂ  ammatory properties 
of these drugs. In a study speciﬁ  cally investigating evidence 
of anti-inﬂ  ammatory activity by roﬂ  umilast, 38 patients with 
COPD were treated with roﬂ  umilast (500 μg od) or placebo 
for 4 weeks. Samples of sputum were collected at week 0, 2 
and 4 with assessment of inﬂ  ammatory cell count, IL-8 levels 
and neutrophil elastase levels assessed at each time point. 
By week 4 roﬂ  umilast had signiﬁ  cantly reduced the number 
of neutrophils and eosinophils (38% and 50%, respectively) 
and furthermore, there was a concomitant reduction in both 
neutrophil elastase and IL-8 levels (Grootendorst et al 2005). 
This data supports the anti-inﬂ  ammatory mode of action of 
PDE4 inhibitors observed in preclinical studies and is also 
consistent with a study which examined sputum inﬂ  am-
matory cell counts and inﬂ  ammatory cell inﬁ  ltration into 
airway tissue in biopsies from patients administered cilomilast 
(15 mg) twice daily for 12 weeks. Although cilomilast did 
not affect sputum cell numbers it signiﬁ  cantly reduced CD8+ 
lymphocyte and macrophage inﬁ  ltration into the airways 
conﬁ  rming the anti-inﬂ  ammatory nature of this drug class 
(Gamble et al 2003) and this appears to correlate with the 
reported beneﬁ  cial effect of cilomilast in COPD (Rennard 
et al 2006) indicating a class effect. 
In the clinical studies described above (summarized 
in Table 1) there was a relatively low incidence of adverse 
events and the side effects reported were mostly mild and 
transient in nature. Examination of the data from a long term 
safety study conducted in patients with COPD showed there 
was no signiﬁ  cant difference in the incidence of adverse 
effects between the placebo control and drug treatment group 
(49% during the ﬁ  rst 26 weeks, 41% thereafter). Greater 
than 90% of these adverse drug events were deemed to be 
unrelated to drug treatment, although this still suggests that 
nearly 10% of adverse events were a result of roﬂ  umilast 
treatment. During the open label extension 10 patients 
(2.5%) experienced adverse side effects which were deﬁ  -
nitely related to roﬂ  umilast and 3 of these patients dropped 
out of the study (Bateman et al 2004). Nevertheless, this still 
represents a small fraction of the total patients on roﬂ  umilast 
and demonstrates that although there is still an incidence 
of class associated side effects, in general administration 
of roﬂ  umilast for up to 52 weeks is safe and well tolerated. 
One further concern with long-term administration of PDE4 
inhibitors is the development of arteriopathy. Arteriopathy 
is a condition associated with arterial necrosis and has 
been observed in rats after treatment with large doses of 
many vasodilators including PDE3 and PDE4 inhibitors, 
adenosine agonists, endothelin receptor antagonists and 
potassium channel openers (Spina 2004). Nevertheless, the 
mechanisms by which these agents induce arteriopathy in 
rats remain to be established, as is whether rats are more 
susceptible to this condition that other species. However, 3 
month treatment with rising, high doses of the PDE4 inhibitor 
N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(triﬂ  uo-
romethyl)-5-quinoline carboxamide (SCH 351591; 12, 24, 
and 48 mg/kg) to cynomolgus monkeys was also associated 
with inﬂ  ammation of the arterioles in many organs and tis-
sues including the mesentery (Losco et al 2004). These data 
suggest that arteriopathy resulting from PDE4 inhibitors is 
not peculiar to the rat and can also be observed in nonhuman 
primates, previously thought resistant to such toxicity. 
These effects observed in animals, are not anticipated to 
be observed in clinical trials as the dose used in humans is 
likely to be a fraction of that used in these toxicity studies. 
Furthermore, theophylline, which has long been used to treat 
asthma and COPD for over half a century, can also induce 
arteriopathy in rats, with no evidence of this occurring in 
humans. Nonetheless, there remains the concern that PDE4 
inhibitors may induce mesenteric inﬂ  ammation in patients 
with asthma and COPD, particularly as gastrointestinal dis-
turbances are the predominant adverse effect see with these 
drugs, although there was no evidence of arteriopathy in 
patients treated with cilomilast (Giembycz 2006).
The data presented in these studies shows that roﬂ  umilast 
is eliciting a moderate anti-inﬂ  ammatory effect in patients 
with COPD. However, the dose which can be administered 
to patients is limited by the side effects associated with the 
drug and thus the full potential of this drug may not be 
realized. Nonetheless, roﬂ  umilast is a new type of treatment 
which speciﬁ  cally targets the underlying inﬂ  ammation, 
mucus secretion, and exacerbations associated with COPD. 
Furthermore quality of life scores, as assessed by the St 
George’s Healthcare Questionnaire improved in patients 
taking roﬂ  umilast, whereas they declined in patients admin-
istered placebo. The improvements in post-bronchodilator 
FEV are less impressive, but given that COPD is associated 
with irreversible airways obstruction, this is not surprising International Journal of COPD 2007:2(2) 128
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given that unlike beta2-adrenoceptor agonists PDE4 
inhibitors are poor bronchoprotective agents. The difﬁ  culty 
with any anti-inﬂ  ammatory drug development programme 
for COPD is the choice of a suitable clinical outcome mea-
sure. This is evident from the recent correspondence in the 
Lancet concerning the utility of roﬂ  umilast in treating COPD 
where it has (Rabe et al 2005). Nevertheless, if roﬂ  umilast 
can attenuate inﬂ  ammation and suppress mucus secretion 
and prevent perpetuation of the decline in lung function in 
COPD patients then it could be deemed a successful drug. 
An application for regulatory approval was submitted for 
Daxas® in the treatment of asthma and COPD to the European 
Medicines Agency (EMEA) in March 2005. However, in 
November 2005 this application was withdrawn until further 
clinical trials are completed and so it is not clear when this 
drug will be licensed. 
Conclusion
It is clear from the few biopsy studies that have been 
undertaken that PDE4 inhibitors induce modest changes in a 
number of important biochemical markers of this disease (eg, 
IL8, neutrophil elastase) that correlated with improvements in 
exacerbation rates, lung function and quality of life, however, 
it remains to be established whether this drug class can 
prevent small airway ﬁ  brosis and emphysema. Nonetheless, 
the clinical experience with roﬂ  umilast suggests that PDE4 
inhibitors with greater tolerability can be developed with 
improved clinical efﬁ  cacy for the treatment of COPD.
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